CelLBxHealth (FRA:DWV) Tariff Resilience Score: 6/10 (As of Jul. 11, 2026)


What is CelLBxHealth Tariff Resilience Score?

CelLBxHealth FRA:DWV -6.06% Tariff Resilience Score is 6 as of Jul. 11, 2026. The stock has 5 warning signs investors should review. Among 215 Medical Diagnostics & Research companies, CelLBxHealth ranks better than 87.44% on this metric.

CelLBxHealth has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

CelLBxHealth has ANGLE PLC's medical technology products are subject to tariffs, but the company has diversified its supply chain. It has moderate pricing power and can mitigate some risks through alternative suppliers. Historical impacts have been manageable.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes CelLBxHealth might have Average Resilient.

CelLBxHealth  (FRA:DWV) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

CelLBxHealth Tariff Resilience Score Related Terms

FRA:DWV vs TMO, DHR, IDXX: Tariff Resilience Score Comparison

For the Diagnostics & Research subindustry, CelLBxHealth's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CelLBxHealth Tariff Resilience Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, CelLBxHealth's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where CelLBxHealth's Tariff Resilience Score falls into.


What does a Tariff Resilience Score of 6 mean?
CelLBxHealth (FRA:DWV) has a Tariff Resilience Score of 6 as of Jul. 11, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, CelLBxHealth ranks #27 out of 215 companies in the Medical Diagnostics & Research industry, placing it in the top 12.6%.
Is CelLBxHealth's Tariff Resilience Score too high?
CelLBxHealth's current Tariff Resilience Score is 6. Based on the distribution chart, CelLBxHealth ranks #27 out of 215 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does CelLBxHealth's Tariff Resilience Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, CelLBxHealth ranks #27 out of 215 companies for Tariff Resilience Score. This places CelLBxHealth in the top 13% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Medical Diagnostics & Research company?
A good Tariff Resilience Score depends on the Medical Diagnostics & Research industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. CelLBxHealth's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CelLBxHealth stock overvalued right now?
CelLBxHealth (FRA:DWV) has a current Tariff Resilience Score of 6. The stock's GF Value™ is €0.07, compared to a current price of €0.02 — trading 77.9% below its estimated fair value. The current Tariff Resilience Score is 6. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For CelLBxHealth (FRA:DWV), the current Tariff Resilience Score is 6 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CelLBxHealth Business Description

Other Exchanges ANPCF:USACLBX:UK
Address 10 Nugent Road, The Surrey Research Park, Surrey, Guildford, GBR, GU2 7AF
CelLBxHealth PLC is active in the healthcare sector in the United Kingdom. The Company's principal trading activity is undertaken in relation to the development and commercialization of the Parsortix cell separation system, with deployment in liquid biopsy that is non-invasive cancer diagnostics. It is a medical diagnostic company specializing in the development of pioneering products in cancer diagnostics. Its patented Parsortix technology can potentially treat and diagnose various forms of cancer. The Parsortix system can capture and harvest CTCs from patient blood. Its geographical segments include Europe and North America, of which the majority of its revenue is generated from Europe.